Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Vanqua Bio Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, so the pending work spans several examination assignments while retaining some examiner-level concentration.
RAO, SAVITHA M is the busiest examiner, with 2 pending actions. Counsel should examine those matters for consistent issues or response opportunities, while treating the matters assigned to the other examiners and art units separately.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §102 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, SAVITHA M | 2 | 60.7% | +29.7% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
| ANDERSON, REBECCA L | 1 | 73.3% | +23.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18700625 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | RAO, SAVITHA M | — |
| 18700445 | OLIGONUCLEOTIDES FOR TARGETING COMPLEMENT C5 | VANHORN, ABIGAIL LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18700617 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | RAO, SAVITHA M | — |
| 18700625 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | RAO, SAVITHA M | — |
| 18700445 | OLIGONUCLEOTIDES FOR TARGETING COMPLEMENT C5 | VANHORN, ABIGAIL LOUISE | — |
| 18288928 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | ANDERSON, REBECCA L | — |
| Art Unit | Apps |
|---|---|
| 1691 | 2 |
| 1636 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18700617 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | RAO, SAVITHA M | 1691 | §112 | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18700625 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | RAO, SAVITHA M | 1691 | §102§112 | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18700445 | OLIGONUCLEOTIDES FOR TARGETING COMPLEMENT C5 | VANHORN, ABIGAIL LOUISE | 1636 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18288928 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | ANDERSON, REBECCA L | 1626 | §102 | Non-Final OA | — | Pending | Oct 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVanqua Bio Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Savitha M Rao has the most, with 2 of Vanqua Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
